| Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (NCT05403580) | Mayo Clinic | 2022-06-03 |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) (NCT06400264) | National Cancer Institute (NCI) | 2022-02-22 |
| Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (NCT05038839) | M.D. Anderson Cancer Center | 2022-02-09 |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (NCT04939090) | Alliance for Clinical Trials in Oncology | 2022-01-03 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (NCT05039801) | M.D. Anderson Cancer Center | 2021-09-30 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942) | National Cancer Institute (NCI) | 2021-08-25 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers (NCT04090619) | M.D. Anderson Cancer Center | 2021-06-22 |
| Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer (NCT04511039) | Roswell Park Cancer Institute | 2021-06-08 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors (NCT04616534) | National Cancer Institute (NCI) | 2021-06-01 |
| Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer (NCT05058339) | M.D. Anderson Cancer Center | 2021-04-27 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (NCT04785287) | M.D. Anderson Cancer Center | 2021-03-29 |
| Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers (NCT04870788) | M.D. Anderson Cancer Center | 2021-03-24 |
| Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers (NCT04062552) | University of Rochester NCORP Research Base | 2021-03-09 |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (NCT04678648) | RasCal Therapeutics, Inc. | 2021-03-03 |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL (NCT04729725) | M.D. Anderson Cancer Center | 2021-02-09 |
| Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer (NCT04697524) | University of California, San Francisco | 2021-01-26 |
| A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma (NCT05101356) | University of California, Davis | 2021-01-13 |
| Patient Considerations of Social Media Account Management After Death (NCT05035667) | M.D. Anderson Cancer Center | 2020-12-22 |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial (NCT04693468) | M.D. Anderson Cancer Center | 2020-12-01 |
| CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study (NCT04552704) | Tianhong Li | 2020-10-30 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas (NCT03925428) | National Cancer Institute (NCI) | 2020-09-18 |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer (NCT04294628) | National Cancer Institute (NCI) | 2020-09-01 |
| Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia (NCT04984551) | M.D. Anderson Cancer Center | 2020-08-24 |
| Technology-Enhanced Palliative Care for Advanced Cancer Patients (NCT04989556) | M.D. Anderson Cancer Center | 2020-08-20 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (NCT04317105) | National Cancer Institute (NCI) | 2020-07-17 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (NCT04197713) | National Cancer Institute (NCI) | 2020-06-30 |
| Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers (NCT04171219) | M.D. Anderson Cancer Center | 2020-03-19 |
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations (NCT04233567) | Sameek Roychowdhury | 2020-01-16 |
| Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (NCT03842228) | National Cancer Institute (NCI) | 2019-11-21 |
| BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (NCT04021043) | M.D. Anderson Cancer Center | 2019-08-19 |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) (NCT06400251) | National Cancer Institute (NCI) | 2019-08-08 |
| A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors (NCT03784677) | M.D. Anderson Cancer Center | 2019-07-29 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) (NCT06400225) | National Cancer Institute (NCI) | 2019-07-24 |
| Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer (NCT03927885) | M.D. Anderson Cancer Center | 2019-03-30 |
| SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies (NCT03831295) | Ronald Levy | 2019-03-13 |
| Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (NCT03830918) | Jonsson Comprehensive Cancer Center | 2019-03-06 |
| Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations (NCT03212274) | National Cancer Institute (NCI) | 2019-01-30 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (NCT03725436) | M.D. Anderson Cancer Center | 2019-01-24 |
| AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification (NCT03253679) | National Cancer Institute (NCI) | 2019-01-16 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) (NCT06400238) | National Cancer Institute (NCI) | 2018-10-15 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) (NCT06308822) | National Cancer Institute (NCI) | 2018-08-20 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | National Cancer Institute (NCI) | 2018-08-13 |
| Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer (NCT03583255) | M.D. Anderson Cancer Center | 2018-06-29 |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) (NCT05490771) | National Cancer Institute (NCI) | 2018-06-20 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (NCT03210714) | National Cancer Institute (NCI) | 2018-06-05 |
| FID-007 in Treating Participants With Advanced Solid Tumors (NCT03537690) | University of Southern California | 2018-05-25 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652) | National Cancer Institute (NCI) | 2018-04-17 |
| Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers (NCT03017833) | M.D. Anderson Cancer Center | 2018-03-12 |
| Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (NCT06385483) | National Cancer Institute (NCI) | 2018-02-28 |
| Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors (NCT03237390) | Mayo Clinic | 2018-01-04 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | National Cancer Institute (NCI) | 2017-11-28 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (NCT03220035) | National Cancer Institute (NCI) | 2017-11-08 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (NCT03065387) | M.D. Anderson Cancer Center | 2017-10-31 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03213691) | National Cancer Institute (NCI) | 2017-10-30 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | National Cancer Institute (NCI) | 2017-09-14 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | National Cancer Institute (NCI) | 2017-08-23 |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) (NCT06390852) | National Cancer Institute (NCI) | 2017-08-21 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (NCT03217747) | M.D. Anderson Cancer Center | 2017-08-02 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | National Cancer Institute (NCI) | 2017-07-31 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) (NCT04439227) | National Cancer Institute (NCI) | 2017-03-24 |
| Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) (NCT06390839) | National Cancer Institute (NCI) | 2017-03-22 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) (NCT06390865) | National Cancer Institute (NCI) | 2017-03-12 |
| Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) (NCT06385496) | National Cancer Institute (NCI) | 2017-03-12 |
| Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors (NCT03035409) | M.D. Anderson Cancer Center | 2017-02-08 |
| Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) (NCT06390826) | National Cancer Institute (NCI) | 2016-11-01 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (NCT02498613) | National Cancer Institute (NCI) | 2016-08-31 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic (NCT02721732) | M.D. Anderson Cancer Center | 2016-08-15 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) (NCT06357975) | National Cancer Institute (NCI) | 2016-07-29 |
| Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (NCT06360575) | National Cancer Institute (NCI) | 2016-07-20 |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) (NCT06357988) | National Cancer Institute (NCI) | 2016-06-20 |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) (NCT04439214) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (NCT04439201) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) (NCT04439123) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) (NCT04439344) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) (NCT04439240) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (NCT04439149) | National Cancer Institute (NCI) | 2016-05-05 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (NCT04439188) | National Cancer Institute (NCI) | 2016-03-21 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (NCT02535312) | National Cancer Institute (NCI) | 2016-03-08 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (NCT04439318) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) (NCT04439175) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (NCT06303167) | National Cancer Institute (NCI) | 2016-01-08 |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) (NCT04439292) | National Cancer Institute (NCI) | 2016-01-04 |
| Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (NCT04439331) | National Cancer Institute (NCI) | 2015-11-19 |
| Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer (NCT02451553) | University of Washington | 2015-11-05 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861) | National Cancer Institute (NCI) | 2015-10-21 |
| Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors (NCT02389309) | M.D. Anderson Cancer Center | 2015-10-05 |
| Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer (NCT02317874) | National Cancer Institute (NCI) | 2015-09-08 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) (NCT04439136) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) (NCT04439279) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) (NCT04439110) | National Cancer Institute (NCI) | 2015-08-12 |